LILRB1 and relapsing-remitting multiple sclerosis: The MS patients with active clinical disease displayed lower levels of LILRB1+ NK cells compared to those in controls or nonactive MS patients, and progressive MS patients displayed higher levels of LILRB1+ CD8+ T lymphocytes and LILRB1+ NK cells compared to those in RRMS patients.